This is a preview of subscription content, log in via an institution to check access.
References
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147(9):1561-4.
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62.
Lubitz SA, Atlas SJ, Ashburner JM, et al. Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial. Circulation. 2022;145(13):946-54.
Kahwati LC, Asher GN, Kadro ZO, et al. Screening for Atrial Fibrillation: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022;327(4):368-83.
Atlas SJ, Ashburner JM, Chang Y, et al. Screening for undiagnosed atrial fibrillation using a single-lead electrocardiogram at primary care visits: patient uptake and practitioner perspectives from the VITAL-AF trial. BMC Prim Care. 2023;24(1):135.
Lubitz SA, Faranesh AZ, Selvaggi C, et al. Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study. Circulation. 2022;146(19):1415-24.
Funding
The study was investigator-initiated and funded by the Bristol Myers Squibb-Pfizer Alliance, which had no role in conducting the trial or analyzing data. All analyses presented were conducted by study investigators independent of the funders.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Dr. Atlas has received sponsored research support from Bristol Myers Squibb / Pfizer and American Heart Association (18SFRN34250007). Dr. Atlas has consulted for Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, and Fitbit. Dr. Ashburner is supported by NIH grant K01HL148506, American Heart Association 18SFRN34250007, and has received sponsored research support from Bristol Myers Squibb / Pfizer. Dr. Ellinor is supported by grants from the National Institutes of Health (RO1HL092577, RO1HL157635), by a grant from the American Heart Association (18SFRN34110082, 961045), and by a grant from the European Union (MAESTRIA 965286). Dr. Ellinor receives sponsored research support from Bayer AG and Novo Nordisk; he has also served on advisory boards or consulted for Bayer AG. Dr. Lubitz is an employee of Novartis. Dr. Lubitz was previously supported by NIH grants R01HL139731 and R01HL157635, and American Heart Association 18SFRN34250007. Dr. Lubitz received sponsored research support from Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Fitbit, Medtronic, Premier, and IBM, and has consulted for Bristol Myers Squibb, Pfizer, Blackstone Life Sciences, and Invitae. Dr. Singer is supported, in part, by the Eliot B. and Edith C. Shoolman Fund of Massachusetts General Hospital. Dr. Singer receives research support from Bristol Myers Squibb-Pfizer and has received consulting fees from Bristol Myers Squibb, Fitbit (Google), Medtronic, and Pfizer. The remaining authors have nothing to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Trial Registration:
ClinicalTrials.gov NCT03979495.
Rights and permissions
About this article
Cite this article
Atlas, S.J., Borowsky, L.H., Chang, Y. et al. Healthcare Resource Utilization Following Single-lead Electrocardiogram Screening for Atrial Fibrillation in Older Individuals at Primary Care Visits. J GEN INTERN MED (2024). https://doi.org/10.1007/s11606-024-08733-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11606-024-08733-7